In a groundbreaking study poised to reshape colorectal cancer prognosis, researchers at Moffitt Cancer Center have unveiled the predictive power of blood-based DNA markers known as protein epiScores. Published in the esteemed journal Clinical Epigenetics, this research pioneers a novel approach that transcends traditional clinical assessments by leveraging the epigenetic landscape of patients’ immune cells. This innovative methodology offers a promising avenue to more accurately forecast cancer recurrence and overall survival, which could profoundly influence patient management and tailored treatment strategies.
Traditional prognostic models for colorectal cancer primarily hinge on tumor pathology and patient demographics such as stage and age. However, such factors have well-documented limitations, often falling short in explaining the variability in patient outcomes. Some patients with ostensibly similar clinical profiles experience dramatically different disease progressions, underscoring the need for biomarkers that capture the underlying biological complexity. Protein epiScores, derived from DNA methylation patterns in circulating immune cells, provide a stable and integrative snapshot of systemic biological states relevant to cancer progression.
DNA methylation, an epigenetic modification involving the addition of methyl groups to DNA molecules, plays a crucial role in regulating gene expression without altering the underlying sequence. In this context, protein epiScores reflect methylation signatures that correlate with the levels of specific plasma proteins involved in key physiological pathways. Unlike direct protein assays, which can be confounded by transient fluctuations and external factors, these methylation-derived scores are remarkably stable over time, capturing the nuanced interplay of immune function, angiogenesis, and hemostasis that underpins tumor behavior.
Central to these findings are four protein epiScores — HCII, VEGFA, CCL17, and LGALS3BP — each linked to distinct biological mechanisms integral to colorectal cancer pathophysiology. HCII (Heparin Cofactor II) is involved in blood coagulation, while VEGFA (Vascular Endothelial Growth Factor A) orchestrates tumor angiogenesis, facilitating blood vessel formation essential for tumor growth. CCL17 plays a role in immune cell trafficking and immune response modulation, and LGALS3BP (Galectin-3 Binding Protein) is implicated in immune regulation and cancer progression. Elevated levels of these markers corresponded to a 60% to 70% higher risk of cancer recurrence, with LGALS3BP notably associated with an 80% increased risk of mortality during follow-up.
The study’s analytical models demonstrated that integrating these protein epiScores with conventional clinical indicators significantly enhanced outcome prediction. Specifically, the accuracy of recurrence prediction improved from 64% to 70%, and overall survival prediction rose from 70% to 75%. These increments, while seemingly modest, signify meaningful advancements in risk stratification, enhancing the capacity to identify patients who may benefit from intensified surveillance or therapeutic interventions. Moreover, the inclusion of these markers refined risk classification for over a third of patients regarding recurrence and for a notable proportion concerning survival.
This research subtly elucidates the intricate biological tapestry that governs colorectal cancer progression. The protein epiScores encompass facets of immune surveillance, vascular remodeling, and coagulation — systems often dysregulated in cancer. By capturing these systemic alterations through epigenetic markers, clinicians gain insights unattainable via tumor-centric measures alone. This systemic viewpoint could illuminate why patients with comparable tumor characteristics diverge in clinical trajectories, highlighting the prognostic value of the tumor microenvironment and host systemic response.
Furthermore, the robustness of DNA methylation as a biomarker source is underscored by its temporal stability and relative insensitivity to acute physiological changes. While plasma protein concentrations may ebb and flow in response to various stimuli, underlying methylation patterns offer a more consistent fingerprint reflective of longer-term biological states. This durability enhances the potential clinical utility of protein epiScores, facilitating their application in routine blood draws conducted at diagnosis or prior to treatment initiation.
Notwithstanding these promising findings, the authors acknowledge the necessity for further validation across diverse patient cohorts and clinical settings. The study lacked data incorporating circulating tumor DNA (ctDNA), an emerging biomarker with established prognostic relevance, necessitating future integrative analyses. Validating these protein epiScores alongside ctDNA and other biomarkers may unlock synergistic prognostic models bolstering personalized oncology care.
Ultimately, the translational potential of this work rests on its simplicity and scalability. Blood draws are minimally invasive and readily standardized, positioning protein epiScore testing as an accessible supplement to existing risk assessment tools. By refining prognosis early in the clinical journey, this biomarker panel may guide therapeutic decisions, optimize follow-up intervals, and minimize unnecessary interventions, thereby aligning treatment intensity with individualized risk.
The implications extend beyond colorectal cancer, as the conceptual framework integrating epigenetics with protein level prediction could be adapted to other malignancies and diseases characterized by complex host-environment interactions. This study exemplifies the transformative capacity of epigenetic research to unravel hidden biological complexity, laying groundwork for precision medicine approaches that honor the multifaceted nature of cancer biology.
As Moffitt Cancer Center continues to propel oncological research forward, this study heralds a new frontier in cancer prognostication, where stable epigenetic markers inform dynamic clinical decisions. It invites the medical community to rethink prognostic paradigms, embracing molecular insights that transcend traditional metrics to enhance patient outcomes.
Subject of Research: People
Article Title: Blood DNA methylation-predicted plasma protein levels and colorectal cancer survival
News Publication Date: February 9, 2026
Web References:
Moffitt Cancer Center: http://moffitt.org/
Colorectal Cancer Overview at Moffitt: https://www.moffitt.org/cancers/colorectal-cancer/
Published Study: https://link.springer.com/article/10.1186/s13148-026-02059-3
DOI: http://dx.doi.org/10.1186/s13148-026-02059-3
References: Clinical Epigenetics, 1-February-2026, Observational Study supported by NIH/National Cancer Institute (P30-CA076292)
Keywords: Cancer research
Tags: blood test for colorectal cancerclinical epigenetics in oncologycolorectal cancer patient management strategiescolorectal cancer survival predictionDNA methylation and cancerepigenetic markers in colorectal cancergroundbreaking research in cancer biomarkersimmune cell analysis in cancer treatmentnovel approaches to cancer prognosispersonalized treatment for cancer patientspredictive biomarkers for cancer recurrenceprotein epiScores in cancer prognosis
